ALZN - Company ID 0001677077
The table below shows Alzamend Neuro, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.07M | -$6.57M | -$8.27M | -$8.92M | -$6.61M | -$2.71M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | -$300.00K | -$147.24K | - | -$106.46K | $100.92K |
| Dividends paid | - | - | - | - | - |
Alzamend Neuro, Inc. reported operating cash flow of -$8.07M for fiscal year 2026. That is down 22.8% from -$6.57M in fiscal 2025. Over the 7 fiscal years shown, operating cash flow declined from -$2.35M (FY 2020) to -$8.07M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $4.83M | $10.44M | $3.65M | $200.00 | $18.85M | $4.45M |